Reactions Weekly

, Volume 1206, Issue 1, pp 3–3 | Cite as

... while UK MHRA releases new safety overview

News item


Melanoma Liver Injury Progressive Multifocal Leukoencephalopathy Natalizumab Safety Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    MHRA, CHM.Natalizumab (Tysabri): safety overview - progressive multifocal leukoencephalopathy, hypersensitivity, and hepatotoxicity. Drug Safety Update 1: 2-4, No. 11, Jun 2008Google Scholar

Copyright information

© Adis International limited or Adis Data Information BV 2008

Personalised recommendations